Recent news on Zoledronic

AUA 2007 - Systemic Therapy of Advanced Prostate Cancer II  -  25 May 2007
UroToday,Patients received one year of androgen deprivation, zoledronic acid at 4 mg evey 3 months and docetaxel at 75 mg/qm for 6 consecutive cycles.

Experts Outline Use of Bisphosphonates Against Myeloma  -  May 24, 2007
HealthCentral.com,Doctors should monitor levels of creatine, a chemical in the body used to measure kidney function, before they give patients pamidronate or zoledronic acid.

Zoledronic Acid Syrup (Zoledronic Acid capsule) Information  -  May 19, 2007
American Chronicle,Zoledronic Acid is used in the Treatment of hypercalcemia of malignancy; treatment of patients with multiple myeloma and bone metastases from solid tumors

Annual osteo shot breaks fracture cycle  -  May 22, 2007
National Review of Medicine,New research shows that zoledronic acid (Aclasta), a drug used to treat Paget's disease, reduced bone fractures in older women by 70% over three years.

Yearly Infusions With Zoledronic Acid Reduce Risk of Fractures in ...  -  May 10, 2007
DG NewsThe three-year study enrolled 3875 women with osteoporosis who were given the IV infusion of 5 mg of zoledronic acid at the start of the study,

Treatment with zoledronic acid effective in reducing fractures in ...  -  May 6, 2007
News-Medical.net,The study showed that treatment with zoledronic acid (marketed as Reclast) was very effective in reducing the incidence of all types of fractures in women

Once-Yearly Zoledronic Acid May Be Helpful for Postmenopausal ...  -  May 2, 2007
Medscape (subscription)May 2, 2007 — Once-yearly infusion of zoledronic acid effectively reduces the risk for vertebral and hip fractures during a 3-year period, according to the

Once-Yearly Zoledronic Acid for Treatment of Postmenopausal ...  -  May 2, 2007
New England Journal of Medicine (subscription),Background A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with

Annual treatment with Zoledronic acid significantly reduces bone ...  -  May 3, 2007
RxPG NEWS,All women involved in the study had postmenopausal osteoporosis and received zoledronic acid Injection or placebo. Results from the study show that

Report On Kidney Cancer Symposium - Management Of Metastatic Sites ...  -  May 21, 2007
Medical News Today (press release),In the recently completed trial that compared zoledronic acid to placebo in decreasing the incidence of skeletal related events, there were 46 patients with

ASCO Releases Updated Guideline On The Role Of Bisphosphonates For ...  -  May 19, 2007
Medical News Today (press release),According to FDA-approved labels of pamidronate and zoledronic acid, the physician also should monitor levels of creatinine, a chemical in the body used to

Once-a-Year IV Drug Scores for Postmenopausal Osteoporosis  -  May 2, 2007
MedPage Today,The once-yearly infusion of zoledronic acid (Reclast) reduced the risk of vetebral, hip, and other fractures in postmenopausal women with osteoporosis,

Once-yearly osteoporosis drug reduces fracture but increases risk ...  -  May 4, 2007
TheHeart.Org,A once-yearly single infusion of zoledronic acid (Reclast, Novartis) during a three-year period significantly reduced the risk of vertebral fracture by 70%,

The Ultimate in Drug Adherence  -  May 16, 2007
HealthandAge.comZoledronic acid (Zometa®) given once-a-year effectively reduces the risk for vertebral and hip fractures in patients with osteoporosis, according to the

Once a Year Drug Treatment for Osteoporosis Shows Promise  -  May 16, 2007
All American Patriots (press release),Cauley was one of the international researchers who worked on the trial of a drug called zoledronic acid. It is a member of a class of drugs called

Yearly anti-osteoporosis jab goes straight to the bone  -  May 8, 2007
Chemistry World,The drug is already marketed by Novartis as Zometa (zoledronic acid) for use in several other disorders, including the genetic bone-softening disorder

'Healthy Bones' Shot Could Cut Women's Fracture Risk  -  May 2, 2007
Atlanta Journal Constitution (subscription),Bisphosphonates, a class of drugs that includes zoledronic acid, are the most commonly used treatment for osteoporosis. They work by slowing the body's

Once-yearly Reclast Significantly Reduced Bone Fractures in Women ...  -  May 3, 2007
PharmaLive.com (press release),These findings have not been observed in other clinical studies or in post-marketing experience from over 1.5 million patients treated with zoledronic acid

Once-yearly Reclast(R) Significantly Reduced Bone Fractures In ...  -  May 3, 2007
Medical News Today (press release),A once-yearly treatment of Reclast(R) (zoledronic acid) Injection significantly reduced the incidence of all types of osteoporotic bone fractures over three

Networks Praise Osteoporosis Drug, Neglect To Credit Novartis  -  May 14, 2007
Seeking Alpha,The wonder drug hailed by both “Evening News� and “World News with Charles Gibson� on May 2 is zoledronic acid. It is sold under the brand names Reclast and

Helen Hayes researchers test promising osteoporosis drug  -  May 3, 2007
Remote Access,Zoledronic acid, made by Novartis and called Reclast, received approval from the Food and Drug Administration last month for use in treating people with

Once-a-year treatment for osteoporosis  -  May 2, 2007
7Online.com,Manhattan resident Bobbi Maxman is feeling great now, after taking an intravenous infusion of a medication called zoledronic acid.

Single annual infusion effective for treating osteoporosis  -  May 2, 2007
Insider Medicine,In this study, researchers assigned nearly 4000 postmenopausal women to receive either a single infusion of zoledronic acid or a placebo every 12 months for

New hope, concern on osteoporosis  -  May 3, 2007
Philadelphia Inquirer,A rare, serious heartbeat irregularity occurred more often in women on the drug, called zoledronic acid, than those given a placebo.

New Drug Being Tested to Treat Osteoporosis  -  May 7, 2007
Voice of AmericaA study found women who got zoledronic acid had dramatically fewer spine and hip fractures than those taking a placebo. The women on zoledronic acid also

New Once A Year Osteoporosis Drug Shows Promise  -  May 3, 2007
Medical News Today,Recently completed international phase III trials on Novartis Pharmaceuticals Corporation's new drug Reclast (zoledronic acid) suggest that a once yearly

Easier-to-take treatment may be an option for osteoporosis  -  May 2, 2007
CBC News,An intravenous version of the oral drug zoledronic acid, which is already used to treat other bone disorders, may prevent hip and spine fractures with one

Looking at an annual boost for brittle bones  -  May 3, 2007
Newsday,Reclast - whose scientific name is zoledronic acid - reduced spinal fractures by 70 percent and hip fractures by 41 percent during the three-year study

Once-a-year drug targets osteoporosis  -  May 3, 2007
Los Angeles Times,The new drug, called zoledronic acid, "requires an encounter with the medical establishment only once a year, so there is no problem with compliance and

Treatment shows promise for brittle bones  -  May 2, 2007
Newsday,Reclast -- whose scientific name is zoledronic acid -- reduced spinal fractures by 70 percent and hip fractures by 41 percent over the three-year study

Osteoporosis drug offers women hope  -  May 2, 2007
Telegraph.co.uk,Patients given a drip into the back of the hand of zoledronic acid, sold as Aclasta, cut the risk of hip breaks by 41 per cent and spinal breaks by 70 per

Infusion reduces breaks in osteoporosis patients  -  May 2, 2007
CTV.ca,The New England Journal of Medicine published new data this week that shows that a 15-minute intravenous infusion of zoledronic acid, also known as Reclast,

Alendronate and Atrial Fibrillation  -  May 2, 2007
New England Journal of Medicine (subscription),HORIZON Pivotal Fracture Trial, (2007). Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. NEJM 356: 1809-1822 [Abstract] [Full Text]

The Risk Of Renal Impairment In Hormone-Refractory Prostate Cancer ...  -  Apr 30, 2007
Medical News Today (press release),UroToday.com- Nearly one-quarter of prostate cancer (CaP) patients treated with zoledronic acid (ZA) suffer renal impairment according to a report by Dr. Oh

New osteoporosis drug  -  May 4, 2007
Sky News Australia,The trial results of a new drug called 'Zoledronic Acid' has seen spine fractures reduced among those involved by 70 per cent and hip fractures down by 41

Scientists hail annual osteoporosis treatment  -  May 3, 2007
ITV.com,During trials in the US, almost 8000 women were given annual 15-minute infusions of zoledronic acid or a placebo over a three-year period.

New Osteoporosis Treatment Looks to be Effective  -  May 4, 2007
Therapeutics Daily (subscription) (press release),The findings on the drug--called zoledronic acid and marketed as Reclast by Novartis Pharmaceuticals--could offer millions of older women a more convenient

New treatment for osteoporosis  -  May 3, 2007
Independent,Researchers behind the trial said that a single infusion of zoledronic acid once a year meant that women could offer protection against the disease without

It's Amazing, It's Incredible, It's Anonymous?  -  May 3, 2007
NewsBustersZoledronic acid “may be just what the doctor ordered,� according to Katie Couric. The broadcasts cited a new study that found a 70-percent decline in spine

Jab brings new hope to bone disease sufferers  -  May 3, 2007
Glasgow Evening Times,Researchers claim that one jab of zoledronic acid a year will protect women victims of osteoporosis and avoid them having to take regular medication.

Cancer patients dig deep to pay for new drugs  -  26 Apr 2007
Globe and Mail,Zoledronic acid for injection (Zometa): A new biophosphonate that helps slow the destruction of bone. It is used to treat cancer that has spread from cancer

Reclast Receives US Approval As A Highly Effective Treatment For ...  -  Apr 23, 2007
Medical News Today (press release),Reclast (zoledronic acid) has received US regulatory approval as the first new treatment in nearly a decade for patients with a bone condition known as

Zoledronic acid for prostate cancer bone metastasis carries risk ...  -  Apr 9, 2007
Therapeutics Daily (subscription) (press release),...of patients with hormone-refractory prostate cancer (HRPC) who are treated with zoledronic acid for bone metastasis, Boston researchers report.

Reclast(R) Receives US Approval As A Highly Effective Treatment ...  -  Apr 18, 2007
Medical News Today (press release),Reclast(R) (zoledronic acid) injection has received US Food and Drug Administration (FDA) approval as the first new treatment in nearly a decade for

Reclast(R) Receives US Approval as a Highly Effective Treatment ...  -  Apr 17, 2007
PR Newswire (press release),Reclast is contraindicated in patients with hypocalcemia (low blood calcium), hypersensitivity to zoledronic acid and in women who are pregnant,

Reclast(R) receives US approval as a highly effective treatment ...  -  Apr 17, 2007
PipelineReview.com (press release),BASEL, Switzerland | Apr 17, 2007 | Reclast(R) (zoledronic acid) has received US regulatory approval as the first new treatment in nearly a decade for

Reclast Receives US Approval as a Highly Effective Treatment for ...  -  Apr 17, 2007
PharmaLive.com (press release),BASEL, Switzerland, April 17, 2007 - Reclast® (zoledronic acid) has received US regulatory approval as the first new treatment in nearly a decade for

FDA OKs Drug for Paget's Disease  -  Apr 17, 2007
WebMDIts active ingredient, zoledronic acid, is also marketed by Novartis under the brand name Zometa for use in certain cancer patients.

Single Annual Zometa Increases Bone Mass in Prostate Cancer  -  Mar 29, 2007
Cancerpage.com,NEW YORK MAR 29, 2007 (Reuters Health) - A single annual treatment with zoledronic acid appears to be sufficient to prevent bone loss in men rendered

Paget Disease Treatment Approved  -  Apr 18, 2007
Facts and Comparisons,S The FDA has approved Novartis’ Reclast (zoledronic acid) injection to be given as a single 5 mg infusion for patients with Paget disease.

MultiVu Video Feed: FDA Approves Reclast(R) the First and Only ...  -  Apr 17, 2007
PR Newswire (press release),NEW YORK, April 17 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved Reclast(R) (zoledronic acid) injection for the treatment of

US approves Novartis' Reclast for bone disease  -  Apr 17, 2007
Therapeutics Daily (subscription) (press release),Novartis said Reclast, or zoledronic acid, had won US approval as the first new treatment in nearly a decade for patients with the disease, which affects

FDA Approves Reclast - Single-Dose Treatment Regimen Tor Paget's  -  Apr 17, 2007
eMaxHealth.com,The US Food and Drug Administration has approved Reclast (zoledronic acid) injection for the treatment of Paget's disease of the bone, the second most

FDA APPROVES RECLAST® THE FIRST AND ONLY SINGLE-DOSE TREATMENT ...  -  Apr 17, 2007
PR Newswire (press release),The US Food and Drug Administration (FDA) has approved Reclast® (zoledronic acid) injection for the treatment of Paget’s disease of the bone,

MultiVu Video Feed: FDA Approves Reclast(R) the First and Only ...  -  Apr 17, 2007
Earthtimes.orgNEW YORK, April 17 -- The US Food and Drug Administration (FDA) has approved Reclast(R) (zoledronic acid) injection for the treatment of Paget's disease of

Novartis licences lead cancer candidate from Antisoma  -  Apr 23, 2007
In-PharmaTechnologist.com,...its current arsenal of anticancer treatments: Femara (letrozole), Glivec (imatinib), Sandostatin LAR (octreotide acetate) and Zometa (zoledronic acid).

Annual Zolodex® Effective in Preventing Bone Loss from Androgen ...  -  Mar 21, 2007
Cancer Consultants (press release),Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Lower Dosing Regimens Of Bisphosphonates Show Antitumor Effects In ...  -  Feb 25, 2007
Medical News Today (press release),A daily dose of zoledronic acid was the most effective method for preventing tumor growth, resulting in tumors that were 88% smaller than those in the

Cancer patients' bone loss is treatable  -  Mar 25, 2007
St. Petersburg Times,Zoledronic acid (Zometa) is an intravenous bisphosphonate used to treat patients with breast and other solid tumors that have metastasized to the bones.

Update in Osteoporosis and Metabolic Bone Disorders  -  Mar 6, 2007
Journal of Clinical Endocrinology and Metabolism,Most impressive are reports on new antiresorptive agents—both bisphosphonates (ibandronate and zoledronic acid) and monoclonal antibodies (MAbs) (denosumab)

Lower Dosing Regimens Of Bisphosphonates Show Antitumor Effects In ...  -  25 Feb 2007
Medical News Today (press release),A daily dose of zoledronic acid was the most effective method for preventing tumor growth, resulting in tumors that were 88% smaller than those in the

Novartis Strategic Healthcare Portfolio Drives Sustained Strong ...  -  18 Jan 2007
PharmaLive.com (press release),Aclasta/Reclast[3] (zoledronic acid) was submitted in late 2006 for approval in the US and EU as a once-yearly bisphosphonate infusion for women with

Zometa® Prevents Bone Loss in Premenopausal Breast Cancer Patients  -  Jan 17, 2007
Cancer Consultants (press release),Researchers affiliated with the Austrian Breast and Colorectal Cancer Study Group have reported that Zometa (zoledronic acid) prevented bone loss in

Alendronate Improves Screw Fixation in Osteoporotic Bone  -  Jan 2, 2007
Journal of Bone and Joint Surgery (subscription)Furthermore, in a canine study, enhancement of bone growth into porous metal implants was found following a single systemic dose of zoledronic acid 6,9 .

Two-Year Z-FAST Trial Shows Zoledronic Acid Prevents Bone Loss in ...  -  Dec 18, 2006
DG NewsSAN ANTONIO, TX -- December 18, 2006 -- Concurrent administration of the third generation bisphosphonate zoledronic acid (Zometa) appears to prevent the bone ...

Zoledronic Acid Plus Letrozole Concurrent Treatment Prevents Bone ...  -  Dec 18, 2006
DG NewsSAN ANTONIO, TX -- December 18, 2006 -- Postmenopausal women taking adjuvant letrozole should also take concurrent zoledronic acid to prevent aromatase ...

Better Outcomes With Zoledronic Acid Thank Pamidronate in Multiple ...  -  Dec 13, 2006
DG News...with multiple myeloma who have elevated bone-specific alkaline phosphate levels appear to have better outcomes if they are treated with zoledronic acid (Zometa ...

Zometa® Prevents Bone Loss in Premenopausal Breast Cancer ...  -  Dec 14, 2006
Cancer Consultants (press release),...women with early-stage breast cancer treated with a combination of hormonal therapies, use of the bisphosphonate drug Zometa® (zoledronic acid) prevented bone ...

Novartis Highlights Strong R&D Pipeline, Plans For Multiple New ...  -  Nov 29, 2006
Medical News Today (press release),...and/or intolerance to treatment with Gleevec/Glivec for certain forms of chronic myeloid leukemia (CML), and also for Aclasta/Reclast (zoledronic acid) as a ...

Study tracks and treats rogue prostate cells  -  Nov 24, 2006
New Zealand Herald,The Radar study will also look at the amount of hormone treatment to administer, and the merits of a drug, zoledronic acid. Zoledronic ...

Novartis Seeks Earlier Drug Approval  -  Nov 28, 2006
Houston Chronicle,...types of leukemia. Aclasta, or zoledronic acid, is an annual infusion for women with postmenopausal osteoporosis. Shares in Novartis ...

MIDDAY BUSINESS REPORT: Elmo’sa hit in Cyber Monday shopping  -  Nov 28, 2006
Kansas City Star,...types of leukemia. Aclasta, or zoledronic acid, is an annual infusion for women with postmenopausal osteoporosis. Basel-based Novartis ...

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional